{
    "symbol": "ALKS",
    "quarter": 3,
    "year": 2022,
    "date": "2022-11-02 13:41:03",
    "content": " So with a strong top line driven by the growth of proprietary products, a specialized commercial infrastructure in neuropsychiatry and addiction and proven drug development capabilities, this stand-alone neuroscience business would represent a significant opportunity to capture operating leverage, drive growth and profitability and advance new potential medicines for neurological disorders. Today, we're refining our expectation for VIVITROL net sales for the full year to a range of $370 million to $380 million, and we continue to expect gross to net adjustments of approximately 51% for the year. And today, we're refining our expectation for ARISTADA net sales for the full year to a range of $300 million to $310 million, and we continue to expect gross to net adjustments of approximately 54% for the year. Today, we're increasing our full year 2022 expectation for LYBALVI net sales from a range of $75 million to $90 million to a range of $88 million to $95 million, including anticipated gross to net adjustments of 27% for the full year. R&D expenses for the third quarter were $100.4 million, reflecting focused investments in the nemvaleukin clinical program and our earlier stage neuroscience and oncology development programs, including preparations for the first-in-human study of ALKS 268. VIVITROL net sales in the third quarter increased approximately 9% year-over-year to $96.5 million, driven primarily by the alcohol dependence indication. Please proceed with your question. Please proceed with your question. Please proceed with your question. Please proceed with your question. Please proceed with your question. Please proceed with your question."
}